[
  {
    "category": "Human",
    "medicine_affected": "Fludarabine",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "fludarabine",
    "therapeutic_area_mesh": "Leukemia",
    "pharmaceutical_forms_affected": "Concentrate for solution for injection/infusion",
    "strengths_affected": "25 mg/ml",
    "availability_of_alternatives": "Unknown",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "The shortage is expected to last until December 2025.",
    "first_published_date": "11/03/2024",
    "last_updated_date": "22/01/2026",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/fludarabine"
  },
  {
    "category": "Human",
    "medicine_affected": "Ozempic",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "semaglutide",
    "therapeutic_area_mesh": "Diabetes Mellitus, Type 2",
    "pharmaceutical_forms_affected": "Pre-filled pen",
    "strengths_affected": "1 mg;0.5 mg;0.25 mg",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "19/10/2022",
    "last_updated_date": "13/01/2026",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/ozempic"
  },
  {
    "category": "Human",
    "medicine_affected": "Fiasp PumpCart (insulin aspart)",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "insulin aspart",
    "therapeutic_area_mesh": "",
    "pharmaceutical_forms_affected": "Solution for injection in a cartridge",
    "strengths_affected": "100 units/mL",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "08/05/2025",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "12/05/2025",
    "last_updated_date": "18/12/2025",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/fiasp-pumpcart-insulin-aspart"
  },
  {
    "category": "Human",
    "medicine_affected": "NovoRapid PumpCart (insulin aspart)",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "insulin aspart",
    "therapeutic_area_mesh": "",
    "pharmaceutical_forms_affected": "Solution for injection in a cartridge",
    "strengths_affected": "100 units/mL",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "08/05/2025",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "12/05/2025",
    "last_updated_date": "18/12/2025",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/novorapid-pumpcart-insulin-aspart"
  },
  {
    "category": "Human",
    "medicine_affected": "Insulin lispro Sanofi",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "insulin lispro",
    "therapeutic_area_mesh": "",
    "pharmaceutical_forms_affected": "Solution for injection in a cartridge;Solution for injection in pre-filled pen",
    "strengths_affected": "100 units/ml solution for injection in cartridges;100 units/ml solution for injection in pre-filled pen",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "The expected duration of the shortage is unknown.",
    "first_published_date": "08/12/2025",
    "last_updated_date": "",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/insulin-lispro-sanofi"
  },
  {
    "category": "Human",
    "medicine_affected": "Dynastat",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "parecoxib",
    "therapeutic_area_mesh": "",
    "pharmaceutical_forms_affected": "Powder and solvent for solution for injection;Powder for solution for injection",
    "strengths_affected": "40 mg",
    "availability_of_alternatives": "Unknown",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "January 2026 in Malta; February 2026 in Greece; March 2026 in Cyprus and France; July 2026 in Bulgaria and Norway",
    "first_published_date": "14/04/2025",
    "last_updated_date": "04/12/2025",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/dynastat"
  },
  {
    "category": "Human",
    "medicine_affected": "ADHD medicines",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "atomoxetine;methylphenidate;lisdexamfetamine",
    "therapeutic_area_mesh": "Attention Deficit Disorder with Hyperactivity",
    "pharmaceutical_forms_affected": "Various presentations in various strengths",
    "strengths_affected": "",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "Depending on the medicine and the EEA country, the shortage may continue until the end of 2025.",
    "first_published_date": "18/12/2023",
    "last_updated_date": "20/11/2025",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/adhd-medicines"
  },
  {
    "category": "Human",
    "medicine_affected": "Risperidone",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "risperidone",
    "therapeutic_area_mesh": "Schizophrenia",
    "pharmaceutical_forms_affected": "Prolonged-release suspension for injection",
    "strengths_affected": "",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "Risperdal Consta - by the end of 2025; Risperidone Teva and Sperizak - to continue until the end of 2026 or beginning of 2027",
    "first_published_date": "19/11/2025",
    "last_updated_date": "",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/risperidone"
  },
  {
    "category": "Human",
    "medicine_affected": "Bronchitol",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "mannitol",
    "therapeutic_area_mesh": "",
    "pharmaceutical_forms_affected": "Inhalation powder",
    "strengths_affected": "40 mg",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "14/11/2025",
    "last_updated_date": "",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/bronchitol"
  },
  {
    "category": "Human",
    "medicine_affected": "Beriglobin",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "human normal immunoglobulin",
    "therapeutic_area_mesh": "Primary Immunodeficiency Diseases;Immunologic Deficiency Syndromes;Hepatitis A;Mucositis",
    "pharmaceutical_forms_affected": "Solution for injection in pre-filled syringe",
    "strengths_affected": "2 ml and 5 ml (160 mg/ml) solution",
    "availability_of_alternatives": "Depending on indication",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "11/11/2025",
    "last_updated_date": "",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/beriglobin"
  },
  {
    "category": "Human",
    "medicine_affected": "Eldisine",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "vindesine",
    "therapeutic_area_mesh": "Leukemia, Promyelocytic, Acute",
    "pharmaceutical_forms_affected": "Solution for injection",
    "strengths_affected": "5 mg",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "End of September 2025",
    "first_published_date": "23/02/2024",
    "last_updated_date": "03/11/2025",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/eldisine"
  },
  {
    "category": "Human",
    "medicine_affected": "Insulin (human insulin) (various short-, rapid-, intermediate-, mixed- and long-acting forms)",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "",
    "therapeutic_area_mesh": "",
    "pharmaceutical_forms_affected": "Solution for injection;Suspension for injection",
    "strengths_affected": "100 units/ml",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "End of 2026",
    "first_published_date": "31/10/2025",
    "last_updated_date": "",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/insulin-human-insulin-various-short-rapid-intermediate-mixed-long-acting-forms"
  },
  {
    "category": "Human",
    "medicine_affected": "Salbutamol inhalation products",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "salbutamol",
    "therapeutic_area_mesh": "Asthma;Pulmonary Disease, Chronic Obstructive",
    "pharmaceutical_forms_affected": "Inhaler;Nebuliser solution",
    "strengths_affected": "",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "05/06/2024",
    "last_updated_date": "31/10/2025",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/salbutamol-inhalation-products"
  },
  {
    "category": "Human",
    "medicine_affected": "Cyanokit",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "hydroxocobalamin",
    "therapeutic_area_mesh": "Poisoning",
    "pharmaceutical_forms_affected": "Powder for solution for infusion",
    "strengths_affected": "",
    "availability_of_alternatives": "",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "19/12/2024",
    "last_updated_date": "30/10/2025",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/cyanokit"
  },
  {
    "category": "Human",
    "medicine_affected": "Pazenir",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "paclitaxel",
    "therapeutic_area_mesh": "Breast Neoplasms",
    "pharmaceutical_forms_affected": "Powder for dispersion for infusion",
    "strengths_affected": "5 mg/ml",
    "availability_of_alternatives": "",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "26/01/2023",
    "last_updated_date": "20/10/2025",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/pazenir"
  },
  {
    "category": "Human",
    "medicine_affected": "Fasturtec",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "rasburicase",
    "therapeutic_area_mesh": "Hyperuricemia",
    "pharmaceutical_forms_affected": "Powder and solvent for concentrate for solution for infusion",
    "strengths_affected": "7.5 mg / 5 ml",
    "availability_of_alternatives": "",
    "start_of_shortage_date": "31/03/2023",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "21/02/2023",
    "last_updated_date": "16/10/2025",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/fasturtec"
  },
  {
    "category": "Human",
    "medicine_affected": "Ixiaro",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "Japanese encephalitis vaccine (inactivated, adsorbed)",
    "therapeutic_area_mesh": "Encephalitis, Japanese;Immunization",
    "pharmaceutical_forms_affected": "Suspension for injection",
    "strengths_affected": "6AU",
    "availability_of_alternatives": "",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "25/05/2023",
    "last_updated_date": "16/10/2025",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/ixiaro"
  },
  {
    "category": "Human",
    "medicine_affected": "Quetiapine",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "",
    "therapeutic_area_mesh": "Schizophrenia;Bipolar Disorder;Depressive Disorder",
    "pharmaceutical_forms_affected": "Extended-release tablet",
    "strengths_affected": "50 mg;150 mg;200 mg;300 mg;400 mg",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "11/03/2025",
    "expected_resolution_date": "",
    "expected_resolution": "Within the second quarter of 2026.",
    "first_published_date": "11/03/2025",
    "last_updated_date": "14/10/2025",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/quetiapine"
  },
  {
    "category": "Human",
    "medicine_affected": "Emend",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "aprepitant",
    "therapeutic_area_mesh": "Vomiting;Postoperative Nausea and Vomiting;Cancer;Neoplasms",
    "pharmaceutical_forms_affected": "Powder for oral suspension",
    "strengths_affected": "80 mg;125 mg",
    "availability_of_alternatives": "",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "12/04/2024",
    "last_updated_date": "14/10/2025",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/emend"
  },
  {
    "category": "Human",
    "medicine_affected": "Human normal immunoglobulins",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "human normal immunoglobulins",
    "therapeutic_area_mesh": "Primary Immunodeficiency Diseases;Immunologic Deficiency Syndromes",
    "pharmaceutical_forms_affected": "Solution for injection/infusion",
    "strengths_affected": "",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "To last until June 2026.",
    "first_published_date": "03/06/2024",
    "last_updated_date": "29/09/2025",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/human-normal-immunoglobulins"
  },
  {
    "category": "Human",
    "medicine_affected": "Ecalta",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "anidulafungin",
    "therapeutic_area_mesh": "Candidiasis",
    "pharmaceutical_forms_affected": "Powder for concentrate for solution for infusion",
    "strengths_affected": "100 mg",
    "availability_of_alternatives": "",
    "start_of_shortage_date": "01/07/2024",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "17/01/2025",
    "last_updated_date": "25/09/2025",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/ecalta"
  },
  {
    "category": "Human",
    "medicine_affected": "Visudyne",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "verteporfin",
    "therapeutic_area_mesh": "Myopia, Degenerative;Macular Degeneration",
    "pharmaceutical_forms_affected": "Powder for solution for infusion",
    "strengths_affected": "15 mg",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "01/05/2020",
    "expected_resolution_date": "",
    "expected_resolution": "Shortages are expected to continue until the end of 2026.",
    "first_published_date": "08/11/2021",
    "last_updated_date": "18/09/2025",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/visudyne"
  },
  {
    "category": "Human",
    "medicine_affected": "Victoza",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "liraglutide",
    "therapeutic_area_mesh": "Diabetes Mellitus, Type 2",
    "pharmaceutical_forms_affected": "Pre-filled pen",
    "strengths_affected": "6 mg/ml",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "03/08/2023",
    "last_updated_date": "05/09/2025",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/victoza"
  },
  {
    "category": "Human",
    "medicine_affected": "Zypadhera",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "olanzapine",
    "therapeutic_area_mesh": "Schizophrenia",
    "pharmaceutical_forms_affected": "Powder and solvent for prolonged-release suspension for injection",
    "strengths_affected": "210 mg;300 mg;405 mg",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "October 2025",
    "first_published_date": "09/07/2024",
    "last_updated_date": "27/08/2025",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/zypadhera"
  },
  {
    "category": "Human",
    "medicine_affected": "Biltricide",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "praziquantel",
    "therapeutic_area_mesh": "Trematode Infections",
    "pharmaceutical_forms_affected": "",
    "strengths_affected": "600 mg film-coated tablets",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "26/08/2025",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "26/08/2025",
    "last_updated_date": "",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/biltricide"
  },
  {
    "category": "Human",
    "medicine_affected": "Moventig",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "",
    "therapeutic_area_mesh": "",
    "pharmaceutical_forms_affected": "",
    "strengths_affected": "12.5 mg;25 mg",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "31 November 2025",
    "first_published_date": "18/08/2025",
    "last_updated_date": "",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/moventig"
  },
  {
    "category": "Human",
    "medicine_affected": "Saxenda",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "liraglutide",
    "therapeutic_area_mesh": "Obesity;Overweight",
    "pharmaceutical_forms_affected": "Solution for injection in pre-filled pen",
    "strengths_affected": "6 mg/ml",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "End of 2025",
    "first_published_date": "24/08/2023",
    "last_updated_date": "25/07/2025",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/saxenda"
  },
  {
    "category": "Human",
    "medicine_affected": "Trulicity",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "dulaglutide",
    "therapeutic_area_mesh": "Diabetes Mellitus, Type 2",
    "pharmaceutical_forms_affected": "Solution for injection in pre-filled pen",
    "strengths_affected": "0.75 mg;1.5 mg;3 mg ;4.5 mg",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "End of 2025",
    "first_published_date": "28/08/2023",
    "last_updated_date": "24/07/2025",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/trulicity"
  },
  {
    "category": "Human",
    "medicine_affected": "Amoxicillin and amoxicillin/clavulanic acid",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "amoxicillin;clavulanic acid",
    "therapeutic_area_mesh": "Bacterial Infections",
    "pharmaceutical_forms_affected": "Various presentations including paediatric formulations and presentations",
    "strengths_affected": "",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "01/10/2022",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "27/01/2023",
    "last_updated_date": "17/06/2025",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/amoxicillin-amoxicillin-clavulanic-acid"
  },
  {
    "category": "Human",
    "medicine_affected": "Perfusion solutions",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "",
    "therapeutic_area_mesh": "Perfusion;Infusions, Intravenous;Therapeutic Irrigation",
    "pharmaceutical_forms_affected": "Intravenous use;Solution for infusion;Irrigation solution",
    "strengths_affected": "",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "End of 2025",
    "first_published_date": "12/06/2025",
    "last_updated_date": "",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/perfusion-solutions"
  },
  {
    "category": "Human",
    "medicine_affected": "NovoSeven (eptacog alfa)",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "eptacog alfa (activated)",
    "therapeutic_area_mesh": "",
    "pharmaceutical_forms_affected": "Powder and solvent for solution for injection",
    "strengths_affected": "1, 2, 5 and 8 mg (50, 100, 250 and 400 KIU)",
    "availability_of_alternatives": "Unknown",
    "start_of_shortage_date": "",
    "expected_resolution_date": "31/12/2025",
    "expected_resolution": "",
    "first_published_date": "12/05/2025",
    "last_updated_date": "05/06/2025",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/novoseven-eptacog-alfa"
  },
  {
    "category": "Human",
    "medicine_affected": "Pegasys",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "peginterferon alfa-2a",
    "therapeutic_area_mesh": "Hepatitis C, Chronic;Hepatitis B, Chronic;Polycythemia Vera;Thrombocythemia, Essential",
    "pharmaceutical_forms_affected": "Solution for injection",
    "strengths_affected": "90 mcg;135 mcg;180 mcg",
    "availability_of_alternatives": "",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "30/10/2024",
    "last_updated_date": "05/06/2025",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/pegasys"
  },
  {
    "category": "Human",
    "medicine_affected": "Champix",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "varenicline",
    "therapeutic_area_mesh": "Tobacco Use Cessation",
    "pharmaceutical_forms_affected": "Film-coated tablet",
    "strengths_affected": "0.5 mg;1 mg",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "June 2025",
    "first_published_date": "08/07/2021",
    "last_updated_date": "28/05/2025",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/champix"
  },
  {
    "category": "Human",
    "medicine_affected": "Zirabev",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "bevacizumab",
    "therapeutic_area_mesh": "Colorectal Neoplasms;Breast Neoplasms;Carcinoma, Non-Small-Cell Lung;Carcinoma, Renal Cell;Uterine Cervical Neoplasms",
    "pharmaceutical_forms_affected": "Concentrate for solution for infusion",
    "strengths_affected": "100mg/4ml ;400mg/16ml",
    "availability_of_alternatives": "",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "17/01/2025",
    "last_updated_date": "10/04/2025",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/zirabev"
  },
  {
    "category": "Human",
    "medicine_affected": "Mimpara",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "cinacalcet",
    "therapeutic_area_mesh": "Hypercalcemia;Parathyroid Neoplasms;Hyperparathyroidism",
    "pharmaceutical_forms_affected": "Tablet;Granules in capsule",
    "strengths_affected": "30, 60, 90mg (tablets);1, 2.5, 5mg (granules in capsule)",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "07/04/2025",
    "last_updated_date": "",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/mimpara"
  },
  {
    "category": "Human",
    "medicine_affected": "RoActemra",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "tocilizumab",
    "therapeutic_area_mesh": "Arthritis, Rheumatoid;Arthritis, Juvenile Rheumatoid;Cytokine Release Syndrome;Giant Cell Arteritis;COVID-19 virus infection",
    "pharmaceutical_forms_affected": "Pre-filled syringe;Pre-filled pen;Solution for subcutaneous injection;Concentrate for solution for infusion",
    "strengths_affected": "162 mg (syringe, pen) ;20 mg/ml (concentrate)",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "03/09/2021",
    "last_updated_date": "01/04/2025",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/roactemra"
  },
  {
    "category": "Human",
    "medicine_affected": "Norditropin NordiFlex",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "somatropin",
    "therapeutic_area_mesh": "Dwarfism, Pituitary",
    "pharmaceutical_forms_affected": "Solution for injection in pre-filled pen",
    "strengths_affected": "5 mg ;10 mg ;15 mg",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "05/12/2023",
    "last_updated_date": "17/12/2024",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/norditropin-nordiflex"
  },
  {
    "category": "Human",
    "medicine_affected": "Cisplatin",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "cisplatin",
    "therapeutic_area_mesh": "Cancer;Neoplasms",
    "pharmaceutical_forms_affected": "Solution for injection",
    "strengths_affected": "",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "06/08/2024",
    "last_updated_date": "",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/cisplatin"
  },
  {
    "category": "Human",
    "medicine_affected": "Fluorouracil",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "fluorouracil",
    "therapeutic_area_mesh": "Cancer;Neoplasms",
    "pharmaceutical_forms_affected": "Solution for injection/infusion",
    "strengths_affected": "",
    "availability_of_alternatives": "",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "2025",
    "first_published_date": "06/08/2024",
    "last_updated_date": "",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/fluorouracil"
  },
  {
    "category": "Human",
    "medicine_affected": "Menopur",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "menotropin",
    "therapeutic_area_mesh": "Infertility",
    "pharmaceutical_forms_affected": "Powder and solvent for solution for injection",
    "strengths_affected": "1200 IU",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "End of 2025",
    "first_published_date": "05/04/2023",
    "last_updated_date": "09/07/2024",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/menopur"
  },
  {
    "category": "Human",
    "medicine_affected": "Creon",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "pancreas powder;pancrelipase",
    "therapeutic_area_mesh": "Pancreatic Diseases",
    "pharmaceutical_forms_affected": "Capsule, hard",
    "strengths_affected": "10,000 units;25,000 units;35,000 units",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "Second half of 2026",
    "first_published_date": "29/04/2024",
    "last_updated_date": "",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/creon"
  },
  {
    "category": "Human",
    "medicine_affected": "Rybelsus",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "semaglutide",
    "therapeutic_area_mesh": "Diabetes Mellitus, Type 2",
    "pharmaceutical_forms_affected": "Tablet",
    "strengths_affected": "3 mg;7 mg;14 mg",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "11/07/2023",
    "last_updated_date": "22/01/2024",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/rybelsus"
  },
  {
    "category": "Human",
    "medicine_affected": "Integrilin",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "eptifibatide",
    "therapeutic_area_mesh": "Angina, Unstable;Myocardial Infarction",
    "pharmaceutical_forms_affected": "Solution for injection;Solution for infusion",
    "strengths_affected": "2 mg/ml (solution for injection);0.75 mg/ml (solution for infusion)",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "17/01/2024",
    "last_updated_date": "",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/integrilin"
  },
  {
    "category": "Human",
    "medicine_affected": "Abraxane",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "paclitaxel",
    "therapeutic_area_mesh": "Breast Neoplasms;Pancreatic Neoplasms;Carcinoma, Non-Small-Cell Lung",
    "pharmaceutical_forms_affected": "Powder for dispersion for injection",
    "strengths_affected": "5 mg/ml",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "11/05/2023",
    "last_updated_date": "18/12/2023",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/abraxane"
  },
  {
    "category": "Human",
    "medicine_affected": "Hycamtin",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "topotecan",
    "therapeutic_area_mesh": "Ovarian Neoplasms;Uterine Cervical Neoplasms;Small Cell Lung Carcinoma",
    "pharmaceutical_forms_affected": "Capsule, hard",
    "strengths_affected": "0.5 mg;1 mg",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "07/11/2023",
    "last_updated_date": "",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/hycamtin"
  },
  {
    "category": "Human",
    "medicine_affected": "Nulojix",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "belatacept",
    "therapeutic_area_mesh": "Graft Rejection;Kidney Transplantation",
    "pharmaceutical_forms_affected": "Solution for infusion",
    "strengths_affected": "25 mg/ml",
    "availability_of_alternatives": "",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "17/03/2017",
    "last_updated_date": "03/10/2023",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/nulojix"
  },
  {
    "category": "Human",
    "medicine_affected": "Kevzara",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "sarilumab",
    "therapeutic_area_mesh": "Arthritis, Rheumatoid",
    "pharmaceutical_forms_affected": "Pre-filled syringe;Pre-filled pen;Solution for subcutaneous injection",
    "strengths_affected": "150 mg;200 mg",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "09/11/2021",
    "last_updated_date": "14/09/2023",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/kevzara"
  },
  {
    "category": "Human",
    "medicine_affected": "Tresiba",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "insulin degludec",
    "therapeutic_area_mesh": "Diabetes Mellitus",
    "pharmaceutical_forms_affected": "Pre-filled pen",
    "strengths_affected": "100 units/ml ;200 units/ml",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "24/08/2023",
    "last_updated_date": "",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/tresiba"
  },
  {
    "category": "Human",
    "medicine_affected": "Methotrexate",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "methotrexate",
    "therapeutic_area_mesh": "Cancer;Neoplasms;Arthritis, Rheumatoid;Arthritis;Psoriasis;Crohn Disease",
    "pharmaceutical_forms_affected": "Solution for injection",
    "strengths_affected": "Various",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "09/08/2023",
    "last_updated_date": "",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/methotrexate"
  },
  {
    "category": "Human",
    "medicine_affected": "Insuman Rapid, Basal and Comb 25 (insulin human)",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "insulin human",
    "therapeutic_area_mesh": "Diabetes Mellitus",
    "pharmaceutical_forms_affected": "Solution for injection;Pre-filled pen",
    "strengths_affected": "3 ml",
    "availability_of_alternatives": "",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "24/01/2023",
    "last_updated_date": "19/07/2023",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/insuman-rapid-basal-comb-25-insulin-human"
  },
  {
    "category": "Human",
    "medicine_affected": "Actilyse and Actilyse Cathflo",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "alteplase",
    "therapeutic_area_mesh": "Myocardial Infarction",
    "pharmaceutical_forms_affected": "Powder and solvent for solution for injection/infusion",
    "strengths_affected": "10 mg (Actilyse);20 mg (Actilyse);50 mg (Actilyse);2 mg (Actilyse Cathflo)",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "23/09/2022",
    "last_updated_date": "11/05/2023",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/actilyse-actilyse-cathflo"
  },
  {
    "category": "Human",
    "medicine_affected": "Metalyse",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "tenecteplase",
    "therapeutic_area_mesh": "Myocardial Infarction",
    "pharmaceutical_forms_affected": "Powder and solvent for solution for injection",
    "strengths_affected": "8,000 units (40 mg);10,000 units (50 mg)",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "23/09/2022",
    "last_updated_date": "11/05/2023",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/metalyse"
  },
  {
    "category": "Human",
    "medicine_affected": "Zerbaxa",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "ceftolozane;tazobactam",
    "therapeutic_area_mesh": "Bacterial Infections",
    "pharmaceutical_forms_affected": "Concentrate for solution for infusion",
    "strengths_affected": "1 g;0.5 g",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "22/12/2020",
    "last_updated_date": "14/04/2023",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/zerbaxa"
  },
  {
    "category": "Human",
    "medicine_affected": "Cetrotide",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "cetrorelix acetate",
    "therapeutic_area_mesh": "Ovulation;Ovulation Induction",
    "pharmaceutical_forms_affected": "Powder and solvent for solution for infusion",
    "strengths_affected": "0.25 mg",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "10/08/2022",
    "last_updated_date": "15/02/2023",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/cetrotide"
  },
  {
    "category": "Human",
    "medicine_affected": "Orgalutran",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "ganirelix",
    "therapeutic_area_mesh": "Reproductive Techniques, Assisted;Ovulation Induction;Infertility, Female",
    "pharmaceutical_forms_affected": "Solution for injection in pre-filled pen",
    "strengths_affected": "0.25 mg/0.5 ml",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "16/02/2017",
    "last_updated_date": "08/11/2022",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/orgalutran"
  },
  {
    "category": "Human",
    "medicine_affected": "Natpar",
    "supply_shortage_status": "Ongoing",
    "international_non_proprietary_name_inn_or_common_name": "parathyroid hormone",
    "therapeutic_area_mesh": "Hypoparathyroidism",
    "pharmaceutical_forms_affected": "Powder and solvent for solution for injection",
    "strengths_affected": "100 micrograms/dose ;75 micrograms/dose ;50 micrograms/dose ;25 micrograms/dose",
    "availability_of_alternatives": "",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "02/05/2022",
    "last_updated_date": "05/10/2022",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/natpar"
  },
  {
    "category": "Human",
    "medicine_affected": "Vfend",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "voriconazole",
    "therapeutic_area_mesh": "Candidiasis;Mycoses;Aspergillosis",
    "pharmaceutical_forms_affected": "Powder for solution for infusion",
    "strengths_affected": "200 mg",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "16/04/2021",
    "last_updated_date": "30/06/2021",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/vfend"
  },
  {
    "category": "Human",
    "medicine_affected": "Respreeza",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "alpha1-proteinase inhibitor (human)",
    "therapeutic_area_mesh": "Genetic Diseases, Inborn;Lung Diseases",
    "pharmaceutical_forms_affected": "Powder and solvent for solution for infusion",
    "strengths_affected": "4,000 mg ;5,000 mg",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "06/04/2021",
    "last_updated_date": "06/05/2021",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/respreeza-0"
  },
  {
    "category": "Human",
    "medicine_affected": "Respreeza",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "alpha1-proteinase inhibitor (human)",
    "therapeutic_area_mesh": "Genetic Diseases, Inborn;Lung Diseases",
    "pharmaceutical_forms_affected": "Powder and solvent for solution for infusion",
    "strengths_affected": "1,000 mg ;4,000 mg ;5,000 mg",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "25/02/2021",
    "last_updated_date": "31/03/2021",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/respreeza"
  },
  {
    "category": "Human",
    "medicine_affected": "Nucala",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "mepolizumab",
    "therapeutic_area_mesh": "Asthma",
    "pharmaceutical_forms_affected": "Pre-filled pen",
    "strengths_affected": "40 mg ;100 mg",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "28/01/2021",
    "last_updated_date": "01/03/2021",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/nucala"
  },
  {
    "category": "Human",
    "medicine_affected": "Cinryze",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "C1 inhibitor (human)",
    "therapeutic_area_mesh": "Angioedemas, Hereditary",
    "pharmaceutical_forms_affected": "Powder and solvent for intravenous injection",
    "strengths_affected": "500 IU",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "06/08/2018",
    "last_updated_date": "25/06/2020",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/cinryze"
  },
  {
    "category": "Human",
    "medicine_affected": "Tygacil",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "tigecycline",
    "therapeutic_area_mesh": "Bacterial Infections;Skin Diseases, Bacterial;Soft Tissue Infections",
    "pharmaceutical_forms_affected": "Powder for solution for infusion",
    "strengths_affected": "",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "22/05/2015",
    "last_updated_date": "07/11/2019",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/tygacil"
  },
  {
    "category": "Human",
    "medicine_affected": "Cerezyme",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "imiglucerase",
    "therapeutic_area_mesh": "Gaucher Disease",
    "pharmaceutical_forms_affected": "Solution for infusion",
    "strengths_affected": "",
    "availability_of_alternatives": "No",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "04/11/2013",
    "last_updated_date": "01/10/2018",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/cerezyme"
  },
  {
    "category": "Human",
    "medicine_affected": "Trisenox",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "arsenic trioxide",
    "therapeutic_area_mesh": "Leukemia, Promyelocytic, Acute",
    "pharmaceutical_forms_affected": "Solution for infusion",
    "strengths_affected": "",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "31/07/2017",
    "last_updated_date": "06/09/2018",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/trisenox"
  },
  {
    "category": "Human",
    "medicine_affected": "Arixtra",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "fondaparinux sodium",
    "therapeutic_area_mesh": "Venous Thrombosis;Pulmonary Embolism;Myocardial Infarction;Angina, Unstable",
    "pharmaceutical_forms_affected": "Pre-filled syringe",
    "strengths_affected": "1.5 mg;2.5 mg;5.0 mg;7.5 mg",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "07/07/2017",
    "last_updated_date": "21/03/2018",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/arixtra"
  },
  {
    "category": "Human",
    "medicine_affected": "Inductos",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "dibotermin alfa",
    "therapeutic_area_mesh": "Tibial Fractures;Fracture Fixation, Internal;Spinal Fusion",
    "pharmaceutical_forms_affected": "Powder, solvent and matrix for implantation matrix",
    "strengths_affected": "",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "16/09/2015",
    "last_updated_date": "15/08/2017",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/inductos"
  },
  {
    "category": "Human",
    "medicine_affected": "Insuman Basal and Comb 25",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "insulin human",
    "therapeutic_area_mesh": "Diabetes Mellitus",
    "pharmaceutical_forms_affected": "Catridge;Pre-filled pen",
    "strengths_affected": "3 ml",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "01/12/2015",
    "last_updated_date": "18/11/2016",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/insuman-basal-comb-25"
  },
  {
    "category": "Human",
    "medicine_affected": "Taxotere",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "docetaxel",
    "therapeutic_area_mesh": "Head and Neck Neoplasms;Carcinoma, Non-Small-Cell Lung;Adenocarcinoma;Prostatic Neoplasms;Stomach Neoplasms;Breast Neoplasms",
    "pharmaceutical_forms_affected": "Concentrate for solution for infusion",
    "strengths_affected": "20 mg;1 ml and 80g;4 ml",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "19/05/2016",
    "last_updated_date": "19/09/2016",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/taxotere"
  },
  {
    "category": "Human",
    "medicine_affected": "Fabrazyme",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "agalsidase beta",
    "therapeutic_area_mesh": "Fabry Disease",
    "pharmaceutical_forms_affected": "Powder for concentrate for solution for infusion",
    "strengths_affected": "5 mg;35 mg",
    "availability_of_alternatives": "No",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "04/11/2013",
    "last_updated_date": "07/06/2016",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/fabrazyme"
  },
  {
    "category": "Human",
    "medicine_affected": "Insuman Rapid, Basal and Comb",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "insulin human",
    "therapeutic_area_mesh": "Diabetes Mellitus",
    "pharmaceutical_forms_affected": "Catridge;Pre-filled pen",
    "strengths_affected": "3 ml",
    "availability_of_alternatives": "Yes",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "31/03/2015",
    "last_updated_date": "25/09/2015",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/insuman-rapid-basal-comb"
  },
  {
    "category": "Human",
    "medicine_affected": "Xofigo",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "radium Ra223 dichloride",
    "therapeutic_area_mesh": "Prostatic Neoplasms",
    "pharmaceutical_forms_affected": "Solution for injection",
    "strengths_affected": "1100 kBq/ml",
    "availability_of_alternatives": "No",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "17/10/2014",
    "last_updated_date": "30/04/2015",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/xofigo"
  },
  {
    "category": "Human",
    "medicine_affected": "Buccolam",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "midazolam",
    "therapeutic_area_mesh": "Epilepsy",
    "pharmaceutical_forms_affected": "Pre-filled syringe",
    "strengths_affected": "2.5 mg;5 mg;7.5 mg;10 mg",
    "availability_of_alternatives": "Not stated",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "25/04/2014",
    "last_updated_date": "30/03/2015",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/buccolam"
  },
  {
    "category": "Human",
    "medicine_affected": "Enbrel",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "etanercept",
    "therapeutic_area_mesh": "Spondylitis, Ankylosing;Arthritis, Juvenile Rheumatoid;Arthritis, Psoriatic;Psoriasis;Arthritis, Rheumatoid",
    "pharmaceutical_forms_affected": "Pre-filled syringe;Pre-filled pen",
    "strengths_affected": "10 mg;25 mg;50 mg",
    "availability_of_alternatives": "No",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "19/02/2014",
    "last_updated_date": "07/05/2014",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/enbrel"
  },
  {
    "category": "Human",
    "medicine_affected": "Increlex",
    "supply_shortage_status": "Resolved",
    "international_non_proprietary_name_inn_or_common_name": "mecasermin",
    "therapeutic_area_mesh": "Laron Syndrome",
    "pharmaceutical_forms_affected": "Solution for subcutaneous injection",
    "strengths_affected": "10 mg/ml",
    "availability_of_alternatives": "No",
    "start_of_shortage_date": "",
    "expected_resolution_date": "",
    "expected_resolution": "",
    "first_published_date": "20/12/2013",
    "last_updated_date": "",
    "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/increlex"
  }
]